Sargent Investment Group LLC Buys 2,520 Shares of Insulet Corporation (NASDAQ:PODD)

Sargent Investment Group LLC raised its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 263.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,475 shares of the medical instruments supplier's stock after buying an additional 2,520 shares during the quarter. Sargent Investment Group LLC's holdings in Insulet were worth $913,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PODD. Larson Financial Group LLC lifted its position in shares of Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 81 shares during the period. Itau Unibanco Holding S.A. bought a new position in Insulet in the fourth quarter valued at about $42,000. Golden State Wealth Management LLC raised its position in Insulet by 553.1% in the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock valued at $55,000 after purchasing an additional 177 shares during the last quarter. Coppell Advisory Solutions LLC increased its stake in shares of Insulet by 135.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after buying an additional 162 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of Insulet by 23.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after buying an additional 59 shares during the period.

Insider Activity

In other news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president owned 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.39% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PODD. Barclays raised their target price on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Wells Fargo & Company set a $322.00 price objective on Insulet in a research note on Monday, April 28th. Citigroup reaffirmed a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Raymond James Financial reaffirmed an "outperform" rating and set a $360.00 target price (up previously from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Finally, Oppenheimer lifted their target price on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $321.00.

Insulet Trading Up 1.3%

PODD stock traded up $3.76 during trading on Tuesday, hitting $284.72. 259,503 shares of the company traded hands, compared to its average volume of 714,608. The firm has a market capitalization of $20.04 billion, a PE ratio of 51.23, a P/E/G ratio of 2.54 and a beta of 1.35. Insulet Corporation has a 1 year low of $173.00 and a 1 year high of $329.33. The company has a 50-day moving average of $309.07 and a 200-day moving average of $281.16. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. Insulet's quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.73 EPS. Analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.